Clinical Trials Directory

Trials / Recruiting

RecruitingNCT05596799

Facing Eating Disorder Fears for Anorexia Nervosa

Facing Eating Disorder Fears for Anorexia Nervosa: a Virtual Relapse Prevention Program Targeted At Approach and Avoidance Behaviors

Status
Recruiting
Phase
N/A
Study type
Interventional
Enrollment
70 (estimated)
Sponsor
University of Louisville · Academic / Other
Sex
All
Age
18 Years – 65 Years
Healthy volunteers
Not accepted

Summary

FED-F is a modular treatment that enhances exposure therapy with psychoeducation and cognitive skills teaching how to face fears of (a) food, (b) weight gain, (c) interoception/body, and (d) social situations. The study goals are to (1) refine and test the acceptability and feasibility of FED-F treatment (Phase I), (2) test if this treatment outperforms treatment as usual (TAU) delivered post-acute treatment as adjunctive to stepdown specialty care (Phase II), and (3) to examine if treatment targets the hypothesized mechanism of action: approach behaviors (Phase II). These goals will lead to a highly deployable and accessible virtual treatment targeted at core AN mechanisms that predict relapse. Specific aims are to (1) refine FED-F into a fully virtual format with input from patients and stakeholders and collect preliminary data (N=10) on its feasibility and acceptability (Phase I), (2) conduct a small pilot RCT (randomized controlled trial) of FED-F (n=30) as compared to TAU (n=30; Phase II), and (3) examine if FED-F targets approach/avoidance behaviors and test if this mechanism is associated with clinical outcomes (Phase II).

Conditions

Interventions

TypeNameDescription
BEHAVIORALFacing Eating Disorder Fears ConditionThe first session consists of diagnosis and general psychoeducation on anorexia nervosa and treatment for anorexia nervosa. After psychoeducation and baseline questionnaires are complete, sessions 2-12 include exposure-based virtual treatment for common eating disorder fears (food, weight gain, body sensations, and social situations).

Timeline

Start date
2022-12-08
Primary completion
2025-08-01
Completion
2025-08-01
First posted
2022-10-27
Last updated
2025-03-30

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT05596799. Inclusion in this directory is not an endorsement.